Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors

Details for Australian Patent Application No. 2005309019 (hide)

Owner Novartis AG

Inventors Manley, Paul W.; Cooke, Nigel Graham

Agent Davies Collison Cave

Pub. Number AU-A-2005309019

PCT Pub. Number WO2006/056399

Priority 60/630,713 24.11.04 US

Filing date 22 November 2005

Wipo publication date 1 June 2006

International Classifications

A61K 31/277 (2006.01)

A61K 31/4025 (2006.01) - not condensed and containing further heterocyclic rings, e.g. cromakalim

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 35/02 (2006.01) Antineoplastic agents

Event Publications

31 May 2007 PCT application entered the National Phase

  PCT publication WO2006/056399 Priority application(s): WO2006/056399

4 March 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005309021-Chocolate composition

2005309018-Two dimensional and three dimensional structures and process for producing same